Strong H1 2026 results driven by 20% biosimilars growth and robust launches, with net sales up 5% at constant currencies and core EBITDA margin expanding to 20.9%. Full-year guidance is confirmed, supported by a strengthened pipeline and solid cash flow.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.